Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PluroGel N for Mildly Infected Diabetic Foot Ulcer
NCT02091596Phase 2Completed
- Sponsor
- PluroGen Therapeutics, LLC
- Start
- Oct 2013
- Primary completion
- Sep 2014
- Modality
- Hydrogel Systems, Transdermal Patches
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PluroGel N in diabetic foot ulcer (DFU) and Infection (2 arms), sponsored by PluroGen Therapeutics, LLC. Primary endpoint: Clinical Response at 14 days. Started Oct 2013; status: completed.
02
Drugs
PluroGel N
03
Conditions
diabetic foot ulcer (DFU)Infection
Beyond the preview
Go deeper on NCT02091596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02091596.